BioCryst Pharmaceuticals BCRX Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities?
- BioCryst Pharmaceuticals (BCRX) reported cash, cash equivalents, and marketable securities of $72.27M in Q1 2026.
- How has BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities increased by 266.2% year-over-year, from $19.74M to $72.27M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.